Re-emerging threat of Trypanosoma cruzi vector transmission in El Salvador, update from 2018 to 2020.


Journal

Infectious diseases of poverty
ISSN: 2049-9957
Titre abrégé: Infect Dis Poverty
Pays: England
ID NLM: 101606645

Informations de publication

Date de publication:
09 Aug 2022
Historique:
received: 26 11 2021
accepted: 13 07 2022
entrez: 9 8 2022
pubmed: 10 8 2022
medline: 12 8 2022
Statut: epublish

Résumé

Since the late twentieth century, Chagas disease gained global attention to suppress the vector burden as a main control strategy in endemic countries. In Central America, multi-national initiative successfully achieved significant reduction in the estimated disease prevalence as well as elimination of the region's principal vector species at the time in 2012. While the last decade has witnessed significant changes in ecosystem-such as urbanization and replacement of the main vector species-that can possibly affect the vector's habitation and residual transmission, the up-to-date vector burden in the region has not been evaluated thoroughly due to the cessation of active vector surveillance. The aim of this study was to update the risk of vector-borne Trypanosoma cruzi infection in El Salvador, the top Chagas disease-endemic country in Central America. A nationwide vector survey was conducted in the domestic environment of El Salvador from September 2018 to November 2020. The selection of the houses for inspection was based on expert purposeful sampling. Infection for T. cruzi was examined by microscopic observation of the insects' feces, followed by a species confirmation using PCR. The data were analyzed using R software version 4.1.3. Proportion estimates with 95% confidence intervals were inferred using the Jeffrey's method provided under the epiR package. A total of 1529 Triatoma dimidiata was captured from 107 houses (infestation rate, 34.4%; 107/311) in all the fourteen departments of the country visited within the period; prevalence of T. cruzi infection was as high as 10% (153/1529). In the country, domestic T. dimidiata infestation was distributed ubiquitously, while T. cruzi infection rates varied across the departments. Five out of fourteen departments showed higher infection rates than the average, suggesting sporadic high-risk areas in the country. Our comprehensive study revealed substantial T. cruzi infection of T. dimidiata across the country, indicating potential active transmission of the disease. Therefore, strengthened surveillance for both vector and human infection is required to truly eliminate the risk of T. cruzi transmission in Central America.

Sections du résumé

BACKGROUND BACKGROUND
Since the late twentieth century, Chagas disease gained global attention to suppress the vector burden as a main control strategy in endemic countries. In Central America, multi-national initiative successfully achieved significant reduction in the estimated disease prevalence as well as elimination of the region's principal vector species at the time in 2012. While the last decade has witnessed significant changes in ecosystem-such as urbanization and replacement of the main vector species-that can possibly affect the vector's habitation and residual transmission, the up-to-date vector burden in the region has not been evaluated thoroughly due to the cessation of active vector surveillance. The aim of this study was to update the risk of vector-borne Trypanosoma cruzi infection in El Salvador, the top Chagas disease-endemic country in Central America.
METHODS METHODS
A nationwide vector survey was conducted in the domestic environment of El Salvador from September 2018 to November 2020. The selection of the houses for inspection was based on expert purposeful sampling. Infection for T. cruzi was examined by microscopic observation of the insects' feces, followed by a species confirmation using PCR. The data were analyzed using R software version 4.1.3. Proportion estimates with 95% confidence intervals were inferred using the Jeffrey's method provided under the epiR package.
RESULTS RESULTS
A total of 1529 Triatoma dimidiata was captured from 107 houses (infestation rate, 34.4%; 107/311) in all the fourteen departments of the country visited within the period; prevalence of T. cruzi infection was as high as 10% (153/1529). In the country, domestic T. dimidiata infestation was distributed ubiquitously, while T. cruzi infection rates varied across the departments. Five out of fourteen departments showed higher infection rates than the average, suggesting sporadic high-risk areas in the country.
CONCLUSIONS CONCLUSIONS
Our comprehensive study revealed substantial T. cruzi infection of T. dimidiata across the country, indicating potential active transmission of the disease. Therefore, strengthened surveillance for both vector and human infection is required to truly eliminate the risk of T. cruzi transmission in Central America.

Identifiants

pubmed: 35945552
doi: 10.1186/s40249-022-01008-5
pii: 10.1186/s40249-022-01008-5
pmc: PMC9361614
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

89

Subventions

Organisme : Science and Technology Research Partnership for Sustainable Development
ID : JP 21jm0110016

Informations de copyright

© 2022. The Author(s).

Références

Clin Infect Dis. 2009 Sep 1;49(5):e52-4
pubmed: 19640226
Diagn Microbiol Infect Dis. 2017 Jul;88(3):225-232
pubmed: 28456430
Infect Dis Poverty. 2021 Sep 15;10(1):117
pubmed: 34526137
Mol Biochem Parasitol. 1989 Mar 15;33(3):205-14
pubmed: 2565018
Wkly Epidemiol Rec. 2015 Feb 6;90(6):33-43
pubmed: 25671846
Parasit Vectors. 2012 Feb 22;5:45
pubmed: 22357219
Mem Inst Oswaldo Cruz. 2002 Jul;97(5):603-12
pubmed: 12219120
Vector Borne Zoonotic Dis. 2007 Winter;7(4):597-606
pubmed: 17979537
Mem Inst Oswaldo Cruz. 2014 Apr;109(2):256-8
pubmed: 24676660
Acta Trop. 2010 Jul-Aug;115(1-2):14-21
pubmed: 19932071
Am J Trop Med Hyg. 2015 Jul;93(1):97-107
pubmed: 25870430
J Infect Dev Ctries. 2014 Aug 13;8(8):1029-36
pubmed: 25116670
Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:17-30
pubmed: 19753454

Auteurs

Marvin Stanley Rodríguez (MS)

Centro de Investigación y Desarrollo en Salud, Universidad de El Salvador, San Salvador, El Salvador.

Yuko Nitahara (Y)

Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Michelle Cornejo (M)

Centro de Investigación y Desarrollo en Salud, Universidad de El Salvador, San Salvador, El Salvador.

Kevin Siliezar (K)

Centro de Investigación y Desarrollo en Salud, Universidad de El Salvador, San Salvador, El Salvador.

Rafael Grande (R)

Centro de Investigación y Desarrollo en Salud, Universidad de El Salvador, San Salvador, El Salvador.

Ana González (A)

Centro de Investigación y Desarrollo en Salud, Universidad de El Salvador, San Salvador, El Salvador.

Kotaro Tasaki (K)

Nagasaki University School of Medicine, Nagasaki, Japan.

Yu Nakagama (Y)

Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Yu Michimuko (Y)

Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Yoko Onizuka (Y)

Graduate School of Health Sciences, Gunma University, 3-39-22 Showamachi, Maebashi, Gunma, 371-8514, Japan.

Junko Nakajima-Shimada (J)

Graduate School of Health Sciences, Gunma University, 3-39-22 Showamachi, Maebashi, Gunma, 371-8514, Japan.

José Eduardo Romero (JE)

Ministerio de Salud, San Salvador, El Salvador.

José Ricardo Palacios (JR)

Centro de Investigación y Desarrollo en Salud, Universidad de El Salvador, San Salvador, El Salvador.

Carmen Elena Arias (CE)

Centro Nacional de Investigaciones Científicas de El Salvador, San Salvador, El Salvador.

William Mejía (W)

Ministerio de Educación, Ciencia y Tecnología, San Salvador, El Salvador.

Yasutoshi Kido (Y)

Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. kidoyasu@omu.ac.jp.
Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. kidoyasu@omu.ac.jp.

Ricardo Cardona Alvarenga (R)

Ministerio de Educación, Ciencia y Tecnología, San Salvador, El Salvador.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH